Assenagon Asset Management
ARCT icon

Assenagon Asset Management’s Arcturus Therapeutics ARCT Stock Holding History

Assenagon Asset Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-55,237
Closed -$1.87M – 1412
2024
Q1 		$1.87M Buy
+55,237
New +$1.96M ﹤0.01% 917

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Assenagon Asset Management's ARCT Position: Q2 2024 in Review

Assenagon Asset Management sold out of Arcturus Therapeutics (ARCT) in Q2 2024, closing a stake of 55,237 shares — an estimated $1.87M sold.

Assenagon Asset Management first reported a position in ARCT in Q1 2024 and held it in 1 quarter. The position peaked at $1.87M in Q1 2024. 170 funds tracked by Wall St. Rank hold ARCT as of Q2 2024.

  • Assenagon Asset Management reported no remaining Arcturus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Assenagon Asset Management sold 55,237 Arcturus Therapeutics shares in Q2 2024, an estimated $1.87M.
  • Assenagon Asset Management first reported a position in Arcturus Therapeutics in Q1 2024 and held it in 1 quarter.
  • Assenagon Asset Management's Arcturus Therapeutics position peaked at $1.87M in Q1 2024.
  • 170 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2024.

Based on Assenagon Asset Management's 13F filing for Q2 2024, filed 18 Jul 2024.